Catheter-directed Sclerotherapy for Ovarian Endometrioma: Short-term Outcomes

Kichang Han, Seok Kyo Seo, Man Deuk Kim, Gyoung Min Kim, Joon Ho Kwon, Hee Joon Kim, Jong Yun Won, Do Yun Lee
Radiology · 2018 · vol. 289(3) , pp. 854–859 · doi:10.1148/radiol.2018180606 · PMID:30152743 · W2889217215
article OA: green CC0 ⤵ 27 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

Catheter-directed sclerotherapy with 95% ethanol reduced ovarian endometrioma size and recurrence with preserved ovarian function and no complications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This prospective study evaluated catheter-directed sclerotherapy using 95% ethanol in 14 participants with primary or recurrent ovarian endometriomas, assessing effects on endometrioma size, pain, serum CA-125, and ovarian reserve via anti-Müllerian hormone (AMH) before treatment and 6 months after, with ultrasound follow-up at multiple time points. Mean endometrioma size decreased significantly from 5.8 cm to 1.1 cm, pain was relieved in all participants, CA-125 levels decreased, and no endometrioma recurrences were reported during a mean follow-up of 12.7 months; AMH did not change, and no procedure-related complications occurred. The main caveats are the small sample size and short-term follow-up without a control group. This paper is centrally about endometriosis — specifically catheter-directed ethanol sclerotherapy for ovarian endometriomas and its short-term outcomes and ovarian reserve effects.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Purpose To evaluate the effectiveness of catheter-directed sclerotherapy (CDS) with 95% ethanol in patients with primary or recurrent ovarian endometriomas. Materials and Methods In this prospective study, 14 participants (mean age, 32 years; range, 20-44 years) who underwent CDS for ovarian endometrioma from March 2015 to December 2017 were evaluated. Diagnosis was based on symptoms and imaging studies. To assess the impact of CDS on ovarian reserve, serum anti-Müllerian hormone (AMH) was measured before CDS and 6 months after CDS. Serum cancer antigen 125 (CA-125) levels were also measured at the same time points. Follow-up US was performed 1, 3, and 6 months after CDS and biannually thereafter to monitor potential cyst size change and recurrence. Comparison of AMH, CA-125, and cyst size before and after CDS was performed by using the paired t test or Wilcoxon signed-rank test. Results Mean endometrioma size decreased from 5.8 cm ± 2.2 to 1.1 cm ± 1 (P ˂ .001). During a mean follow-up of 12.7 months (range, 6.1-23.0 months), there were no recurrences of endometrioma. Pain was relieved in all participants, with a decrease in serum CA-125 level (P = .001). There was no difference in serum AMH level before and 6 months after CDS, indicating well-preserved ovarian function (4.29 ng/mL ± 2.47 vs 4.36 ng/mL ± 1.94, respectively; P > .875). There were no procedure-related complications. Conclusion Catheter-based sclerotherapy with 95% ethanol can lead to better short-term clinical outcomes and well-preserved ovarian function for patients with endometriomas. © RSNA, 2018.

My notes (saved in your browser only)

Condition tags

endometriosisendometrioma

MeSH descriptors

Endometriosis Ovarian Diseases Sclerotherapy Sclerotherapy Adult Catheters Endometriosis Endometriosis Ethanol Ethanol Female Fluoroscopy Humans Ovarian Diseases Ovarian Diseases Ovary Ovary Prospective Studies Radiography, Interventional Sclerotherapy

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (23)

Cited by (27)

Source provenance

europepmc
last seen: 2026-06-16T06:07:01.518242+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:37.156494+00:00
License: CC0 · commercial use OK